Replies to post #520030 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

:-)

[ilovetech]

ATL- Exactly, the distinction you've made warrants further confidence for approval. When these fast track programs were being thought through, they wouldn't have assume advanced treatments would come cheap.

ILT

[LearningEveryTrade]

Yes. This.

[meirluc]

ATL, at this time the average life expectancy of ndGBM patients treated with either DCVax-L or the helmet is let's say around 20 months. The helmet treatment cost would therefore be around $420,000 (21,000X20=420,000) whereas the cost for the DCVax-L treatment would be around $200,000.

However, the longer living patients (50% of the patients) of both treatment groups, have a wider range (distribution) of survival (20-60 months) than the 50% shorter living group of patients who survive about 6-20 months. I therefore believe that the average cost of the helmet treatment could perhaps be triple the cost incurred by
DCVax-L. For example, quite a number of patients survive past 36 months and the treatment cost for their DCVax-L treatment would be capped at $200,000 whereas the cost of the helmet treatment would be $756,000 (36X21,000=756,000).